Wolfgang Miesbach: Six Years of Normal Factor VIII After a Single Gene Therapy in Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Kerstin Herbst et al, published in Haemophilia:
“One single infusion.
Normal Factor VIII for six years – even after Grade 3 ALT elevation.
A new case report about a remarkable 6-year follow-up of a patient with severe haemophilia A treated with valoctocogene roxaparvovec within the GENEr8-1 study.
Six full years after a single gene therapy infusion, the patient maintains normal FVIII activity (49-72 IU/dL by chromogenic assay in year 6) – with zero bleeding episodes and no prophylactic FVIII infusions since treatment.
FVIII levels appear to have reached a plateau from year 3 onwards, pointing to durable, long-term transgene expression.
What makes this case particularly instructive is the immunosuppression management:
- Grade 3 ALT elevation (peak 555 U/L) at week 5 required hospitalisation and IV methyl-prednisolone
- Oral prednisolone was switched to budesonide to reduce systemic side effects (incl. oral thrush) – while FVIII levels remained protected
- Total immunosuppression lasted approximately 40 weeks – personalised, stepwise, and carefully tapered
For context: in the GENEr8-1 trial overall, only 8.3% of patients maintained FVIII more than 40 IU/dL at 5 years.
This case demonstrates that with tailored immunosuppression, significantly better long-term outcomes are within reach – even after a serious hepatic immune response.
Congratulations to Kerstin Herbst, Behnaz Pezeshkpoor and co-authors from the University of Bonn (Johannes Oldenburg).”
Title: Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels
Authors: Kerstin Herbst, Behnaz Pezeshkpoor, Claudia Klein, Thilo Albert, Philipp Lutz, Christian Strassburg, Ulrich Spengler, Georg Goldmann, Johannes Oldenburg
Read the Full Article on Haemophilia

Simon Fletcher, Research Assistant at University of Oxford, shared this post, adding:
“An interesting paper, but yet again, there is no discussion of the psychosocial impacts of either the gene therapy itself or the immunosuppression required to treat the ALT elevation.
Case reports are important but they should be more than just a report of the physical outcomes to a treatment or incident.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 14, 2026, 00:04Carlos A. Metidieri Menegozzo: The First Priority in Trauma Transfusion May Be Time to First Blood Product
-
Nov 13, 2026, 23:43Alamgir Hosen Ronit: Corrected Platelet Count in EDTA Induced Platelet Aggregation
-
Nov 13, 2026, 23:32Evi Loos: Can PRP Improve Pain in Thumb Base Osteoarthritis?
-
Nov 13, 2026, 23:10Cesar de Almeida Neto: Digital Connectivity Can Transform Plateletpheresis Practice
-
Nov 13, 2026, 23:10Chien-Wen Liew: Where PRP Actually Sits in the Evidence
-
Nov 13, 2026, 23:08Erika Koppers: Continuing the Collaborative Journey Towards Equitable Haemophilia Care in South Africa
-
Nov 13, 2026, 23:06Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A
-
Nov 13, 2026, 22:57Rolf Bekendam: Moderating a Conversation With Experts on Rare Bleeding Disorders
-
Nov 13, 2026, 16:17Shailendra Singh: Bombay Hospital Jaipur Inaugurates New Facility with Voluntary Blood Donation Camp